Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Health and Drug Alerts

Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness

Eric Wooltorton
CMAJ January 08, 2002 166 (1) 68-68-a;
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Metrics
  • Responses
  • PDF
Loading

Reason for posting: In a letter to health professionals,1 Health Canada and GlaxoSmithKline stated that 1127 reports of suspected adverse drug reactions for bupropion were received between May 1998 and May 28, 2001. Included were reports of 19 deaths (including 1 case of liver failure, 1 case of myocarditis, 3 cases of suicide), 172 reports of seizures or convulsions and 37 reports of serum-sickness-like reactions. Although cause- and- effect relations have not been established in the vast majority of the reports, it is important to remind physicians and warn patients of possible adverse effects of this medication.

The drug: Bupropion appears to block noradrenergic reuptake and dopaminergic reuptake in the brain. It is used as an antidepressant (marketed in Canada as Wellbutrin SR) and as a smoking cessation aid (marketed in Canada as Zyban). Common adverse events include dry mouth and insomnia, nausea, headache and rash.2 Bupropion is known to reduce seizure thresholds, with a seizure rate of about 1 in 1000 subjects treated.3 Anaphylactoid reactions, including dyspnea, angioedema, urticaria and pruritus, have been reported at a rate of 1 to 3 cases per 1000 patients enrolled in clinical trials.2 Symptoms of arthralgias, myalgias and fever and rash resembling serum sickness have been reported rarely. For detailed descriptions of drug interactions and adverse effects, see the product monograph.

What to do: Patients should be warned of the risks of potential serious adverse effects of these medications, including seizures and allergic reactions. Zyban and Wellbutrin SR should not be administered concurrently, nor should they be prescribed to patients with a seizure disorder. Furthermore, bupropion should not be administered to patients with conditions altering the seizure threshold, including anorexia nervosa or bulimia, patients with potential benzodiazepine or alcohol withdrawal, those with head trauma or central nervous system pathology, or patients taking antipsychotic drugs, systemic steroids, quinolone antibiotics or antimalarial drugs. Doses should be limited to no more than 150 mg per single dose and to no more than 300 mg per day. If a seizure or allergic reaction occurs, the medication should be discontinued and appropriate medical attention sought. To avoid prolonged QT intervals and ventricle arrhythmias secondary to thioridazine toxicity, bupropion should not be administered if a monoamine oxidase inhibitor or thioridazine antipsychotic drug has been given within the past 14 days. Bupropion is contraindicated in patients with severe hepatic impairment. A patient information sheet is now available online.4

Eric Wooltorton CMAJ

References

  1. 1.↵
    Health Canada, GlaxoSmithKline. Important safety information regarding bupropion. July 3, 2001. Available: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/zyban_e.html (accessed 2001 Nov 26).
  2. 2.↵
    Zyban, bupropion hydrochloride 150 mg sustained release tablets smoking cessation aid [product monograph]. Mississauga (ON): GlaxoSmithKline; 2001 July 5.
  3. 3.↵
    Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-202.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Health Canada. Safety information for patients taking Zyban. Available: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/zyban2_e.pdf (accessed 2001 Nov 29).
PreviousNext
Back to top

In this issue

CMAJ
Vol. 166, Issue 1
8 Jan 2002
  • Table of Contents
  • Index by author
  • Canadian Adverse Drug Reaction Newsletter (85-94)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness
Eric Wooltorton
CMAJ Jan 2002, 166 (1) 68-68-a;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness
Eric Wooltorton
CMAJ Jan 2002, 166 (1) 68-68-a;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION
  • Drug safety without borders: concerns about bupropion
  • Google Scholar

More in this TOC Section

  • Nefazodone (Serzone) withdrawn because of hepatotoxicity
  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
  • Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Drugs: psychotherapeutic
    • Drugs: adverse reactions

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, CMA Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire